News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyprotex (COTXF.PK) - Contract With U.S. EPA



5/1/2013 10:57:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

1 May 2013 - Cyprotex PLC (AIM: CRX), the specialist preclinical contract research organisation today announces that the U.S. Environmental Protection Agency (EPA) has awarded the Company the contract to obtain contractor services in support of the EPA’s ongoing ToxCast Project relating to the Prioritization of Environmentally Relevant Chemicals. Cyprotex will be providing High Content Imaging Bioassay Analysis of the ToxCast Compound Library. The contract commenced on 25 April 2013 and runs for a period of five years. The delay in concluding this contract was referred to in the Chairman’s comment in the Company’s Interim Results announcement of 6 September 2012.

For further information:

Cyprotex PLC Tel: +44 (0) 1625 505 100

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

Mark Warburton, Chief Operating Officer and Legal Counsel ir@cyprotex.com

www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496 3000

Shaun Dobson

Jenny Wyllie

shaun.dobson@nplus1singer.com

jenny.wyllie@nplus1singer.com

www.nplus1singer.com

FTI Consulting Tel: +44 (0) 20 7831 3113

Simon Conway

Mo Noonan cyprotex@fticonsulting.com

www.fticonsulting.com

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services , including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
EPA
Cyprotex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES